Copyright Reports & Markets. All rights reserved.

Global Antiviral Drugs Market Research Report 2021

Request for Sample of this report
Buy now

1 Antiviral Drugs Market Overview

  • 1.1 Product Overview and Scope of Antiviral Drugs
  • 1.2 Antiviral Drugs Segment by Type
    • 1.2.1 Global Antiviral Drugs Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Reverse Transcriptase Inhibitors
    • 1.2.3 Protease Inhibitors
    • 1.2.4 Fusion Inhibitors
    • 1.2.5 Immune System Modulators
  • 1.3 Antiviral Drugs Segment by Application
    • 1.3.1 Antiviral Drugs Sales Comparison by Application: (2021-2027)
    • 1.3.2 Hepatitis Therapeutics
    • 1.3.3 HIV/AIDS Therapeutics
    • 1.3.4 Herpes Therapeutics
    • 1.3.5 Influenza Therapeutics
  • 1.4 Global Antiviral Drugs Market Size Estimates and Forecasts
    • 1.4.1 Global Antiviral Drugs Revenue 2016-2027
    • 1.4.2 Global Antiviral Drugs Sales 2016-2027
    • 1.4.3 Antiviral Drugs Market Size by Region: 2016 Versus 2021 Versus 2027

2 Antiviral Drugs Market Competition by Manufacturers

  • 2.1 Global Antiviral Drugs Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Antiviral Drugs Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Antiviral Drugs Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Antiviral Drugs Manufacturing Sites, Area Served, Product Type
  • 2.5 Antiviral Drugs Market Competitive Situation and Trends
    • 2.5.1 Antiviral Drugs Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Antiviral Drugs Players Market Share by Revenue
    • 2.5.3 Global Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Antiviral Drugs Retrospective Market Scenario by Region

  • 3.1 Global Antiviral Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global Antiviral Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America Antiviral Drugs Market Facts & Figures by Country
    • 3.3.1 North America Antiviral Drugs Sales by Country
    • 3.3.2 North America Antiviral Drugs Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Antiviral Drugs Market Facts & Figures by Country
    • 3.4.1 Europe Antiviral Drugs Sales by Country
    • 3.4.2 Europe Antiviral Drugs Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Antiviral Drugs Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Antiviral Drugs Sales by Region
    • 3.5.2 Asia Pacific Antiviral Drugs Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Antiviral Drugs Market Facts & Figures by Country
    • 3.6.1 Latin America Antiviral Drugs Sales by Country
    • 3.6.2 Latin America Antiviral Drugs Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Antiviral Drugs Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Antiviral Drugs Sales by Country
    • 3.7.2 Middle East and Africa Antiviral Drugs Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 U.A.E

4 Global Antiviral Drugs Historic Market Analysis by Type

  • 4.1 Global Antiviral Drugs Sales Market Share by Type (2016-2021)
  • 4.2 Global Antiviral Drugs Revenue Market Share by Type (2016-2021)
  • 4.3 Global Antiviral Drugs Price by Type (2016-2021)

5 Global Antiviral Drugs Historic Market Analysis by Application

  • 5.1 Global Antiviral Drugs Sales Market Share by Application (2016-2021)
  • 5.2 Global Antiviral Drugs Revenue Market Share by Application (2016-2021)
  • 5.3 Global Antiviral Drugs Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Roche
    • 6.1.1 Roche Corporation Information
    • 6.1.2 Roche Description and Business Overview
    • 6.1.3 Roche Antiviral Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Roche Product Portfolio
    • 6.1.5 Roche Recent Developments/Updates
  • 6.2 Johnson & Johnson
    • 6.2.1 Johnson & Johnson Corporation Information
    • 6.2.2 Johnson & Johnson Description and Business Overview
    • 6.2.3 Johnson & Johnson Antiviral Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Johnson & Johnson Product Portfolio
    • 6.2.5 Johnson & Johnson Recent Developments/Updates
  • 6.3 Merck
    • 6.3.1 Merck Corporation Information
    • 6.3.2 Merck Description and Business Overview
    • 6.3.3 Merck Antiviral Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Merck Product Portfolio
    • 6.3.5 Merck Recent Developments/Updates
  • 6.4 Novartis
    • 6.4.1 Novartis Corporation Information
    • 6.4.2 Novartis Description and Business Overview
    • 6.4.3 Novartis Antiviral Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Novartis Product Portfolio
    • 6.4.5 Novartis Recent Developments/Updates
  • 6.5 Bristol-Myers Squibb
    • 6.5.1 Bristol-Myers Squibb Corporation Information
    • 6.5.2 Bristol-Myers Squibb Description and Business Overview
    • 6.5.3 Bristol-Myers Squibb Antiviral Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Bristol-Myers Squibb Product Portfolio
    • 6.5.5 Bristol-Myers Squibb Recent Developments/Updates
  • 6.6 Gilead Sciences
    • 6.6.1 Gilead Sciences Corporation Information
    • 6.6.2 Gilead Sciences Description and Business Overview
    • 6.6.3 Gilead Sciences Antiviral Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Gilead Sciences Product Portfolio
    • 6.6.5 Gilead Sciences Recent Developments/Updates
  • 6.7 GlaxoSmithKline
    • 6.6.1 GlaxoSmithKline Corporation Information
    • 6.6.2 GlaxoSmithKline Description and Business Overview
    • 6.6.3 GlaxoSmithKline Antiviral Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 GlaxoSmithKline Product Portfolio
    • 6.7.5 GlaxoSmithKline Recent Developments/Updates
  • 6.8 AbbVie
    • 6.8.1 AbbVie Corporation Information
    • 6.8.2 AbbVie Description and Business Overview
    • 6.8.3 AbbVie Antiviral Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 AbbVie Product Portfolio
    • 6.8.5 AbbVie Recent Developments/Updates

7 Antiviral Drugs Manufacturing Cost Analysis

  • 7.1 Antiviral Drugs Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Antiviral Drugs
  • 7.4 Antiviral Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Antiviral Drugs Distributors List
  • 8.3 Antiviral Drugs Customers

9 Antiviral Drugs Market Dynamics

  • 9.1 Antiviral Drugs Industry Trends
  • 9.2 Antiviral Drugs Growth Drivers
  • 9.3 Antiviral Drugs Market Challenges
  • 9.4 Antiviral Drugs Market Restraints

10 Global Market Forecast

  • 10.1 Antiviral Drugs Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Antiviral Drugs by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Antiviral Drugs by Type (2022-2027)
  • 10.2 Antiviral Drugs Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Antiviral Drugs by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Antiviral Drugs by Application (2022-2027)
  • 10.3 Antiviral Drugs Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Antiviral Drugs by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Antiviral Drugs by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Reverse Transcriptase Inhibitors
    Protease Inhibitors
    Fusion Inhibitors
    Immune System Modulators

    Segment by Application
    Hepatitis Therapeutics
    HIV/AIDS Therapeutics
    Herpes Therapeutics
    Influenza Therapeutics

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E

    By Company
    Roche
    Johnson & Johnson
    Merck
    Novartis
    Bristol-Myers Squibb
    Gilead Sciences
    GlaxoSmithKline
    AbbVie

    Buy now